PainReform Ltd. (PRFX) Announces Name Change, Shares Surge 27.4%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Source: Benzinga
- Significant Stock Surge: PainReform Ltd. shares rose 27.4% to $1.02 in pre-market trading following the announcement of a name change and expansion into diversified healthcare and AI-driven energy platforms, indicating strong market confidence in its new strategy.
- Diversification Strategy: The name change reflects the company's strategic shift towards healthcare and energy sectors, aiming to attract more investors and enhance brand recognition, thereby strengthening its competitive position in the market.
- Market Movements: In pre-market trading, Acco Group Holdings saw a staggering 219.4% increase, highlighting strong investor interest in high-growth potential companies, which may influence perceptions of other related stocks.
- Industry Trends: As the integration of healthcare and energy sectors accelerates, PainReform's strategic adjustments align with industry developments and could provide the company with long-term growth opportunities.
Analyst Views on PRFX
About PRFX
PRF Technologies Ltd, formerly known as PainReform Ltd, isn a Israel-based pharmaceutical Company. The Company is focused on reformulating established pain therapeutics using an extended-release drug-delivery system designed to prolong postoperative analgesia and reduce reliance on opioids. The Company's product, PRF-110, is an oil-based, long-acting formulation of ropivacaine applied directly into surgical wounds to provide localized, extended pain relief, and the Company has also developed patented versions combining ropivacaine with dexamethasone to enhance both analgesic and anti-inflammatory effects. The Company's development strategy leverages available legal means to accelerate commercialization of improved non-opioid pain-management products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
